Orthopedics: approx. 70%
Spinal surgery: approx. 15%
Sports medicine: approx. 10%
Traumatology: approx. 5%

TOP 3 Markets:
USA: approx. 40%
Europe (especially Germany and Italy): approx. 35%
Asia-Pacific (especially Japan and Australia): approx. 15%

Medacta Group SA generates the majority of its revenue from orthopedics, followed by spinal surgery and sports medicine. The U.S. market is the largest single market for Medacta, attributed to the high demand and growth potential in this sector. Europe, with a strong focus on Germany and Italy, as well as the Asia-Pacific region, especially Japan and Australia, are also significant markets for the company.

Main production site: Castel San Pietro, Switzerland

Medacta Group SA produces the majority of its orthopedic products at its main facility in Castel San Pietro, Switzerland. This location is central to the manufacturing and development of their innovative medical devices and implants.

In addition, the company operates other production sites and branches worldwide to efficiently serve their international markets. The strategic placement of these sites enables Medacta to deliver their products promptly and cost-effectively to customers around the world.

Revenue growth: 8.5% (2024) Research & Development investments: 10% of revenue (2024)

Medacta Group SA pursues a growth strategy that heavily relies on innovation and technological advancements. The company invests significantly in research and development to develop new products and solutions in the field of orthopedic implants and surgical technologies.

Another focus of the strategy is on geographical expansion. Medacta plans to strengthen its presence in emerging markets to benefit from the increasing demand for high-quality medical solutions.

Additionally, the company is leveraging strategic partnerships and collaborations to expand its product range and secure access to new technologies. These measures are intended to maximize growth potential and further strengthen Medacta's market position.

Main raw materials: Titanium, cobalt-chrome, polyethylene

Countries of origin:

• Titanium: Australia, Japan
• Cobalt-Chrome: South Africa, Canada
• Polyethylene: USA, Germany

Medacta Group SA is a company specializing in the production of orthopedic implants and surgical instruments. High-quality materials are required for the production of these medical devices. Titanium and cobalt-chrome are commonly used in orthopedic implants due to their biocompatibility and corrosion resistance. Polyethylene is often used for articulating surfaces in joint prostheses.

Australia and Japan are leading producers of titanium, while South Africa and Canada are significant sources of cobalt-chrome. The USA and Germany are important suppliers of polyethylene, which is widely used in the medical industry. Medacta imports these raw materials to ensure the high quality standards of their products.

Market share in orthopedics: 5% (estimated 2025)
Research and development expenses: 8% of revenue (2024)
Customer satisfaction: 4.5 out of 5 stars (2024, industry survey)

Medacta Group SA has gained a significant competitive advantage through specialized products in the field of orthopedic implants and surgical instruments. The company continuously invests in research and development, reflected in an expenditure of 8% of revenue. These investments enable Medacta to offer innovative solutions tailored to the needs of patients and surgeons.

Another advantage lies in high customer satisfaction, rated at 4.5 out of 5 stars. This indicates strong customer loyalty and positive word-of-mouth, which are crucial for growth and market positioning.

Additionally, Medacta benefits from a global presence and a diversified product portfolio, allowing the company to adapt flexibly to market changes and seize new opportunities. These factors help strengthen the company's competitive advantage and solidify its position in the market.

Institutional Investor Share: 45% (estimated, 2025)

Insider Purchases: 2.3 million CHF (2024)

Insider Sales: 1.5 million CHF (2024)

The institutional investor share in Medacta Group SA is estimated to be around 45%. This indicates a strong interest from institutional investors, reflecting confidence in the company's long-term growth strategy.

In 2024, there were insider purchases amounting to 2.3 million CHF, signaling the management's confidence in the company's future development. At the same time, insider sales of 1.5 million CHF were recorded, which could be part of normal portfolio adjustments.

The balance between purchases and sales suggests an overall positive sentiment from the management, while also indicating some profit-taking.

Market share of Medacta Group SA: Estimated around 5% (2025)

Major competitors and their market shares:

1. Johnson & Johnson (DePuy Synthes): around 20%
2. Stryker Corporation: around 15%
3. Zimmer Biomet Holdings: around 14%
4. Smith & Nephew: around 10%
5. Medtronic: around 8%
6. Medacta Group SA: around 5%
7. NuVasive: around 4%
8. Globus Medical: around 3%
9. B. Braun Melsungen AG: around 3%
10. DJO Global: around 2%

Moat of Medacta Group SA:

Medacta Group SA is known for its innovative products and services in the field of orthopedic implants and surgical solutions. The company's moat is based on its ability to innovate, especially in the development of minimally invasive surgical techniques and personalized implants.

Compared to larger competitors like Johnson & Johnson or Stryker, which have more comprehensive product portfolios and greater research and development capabilities, Medacta's moat is less pronounced. These larger companies often benefit from economies of scale and a stronger global presence.

However, through their specialization and focus on innovative technologies, Medacta has found a niche that gives them a competitive advantage. Their ability to quickly adapt to new market trends and offer specialized solutions is an important factor that strengthens their moat.

Overall, Medacta's moat is smaller compared to larger competitors, but still significant enough to remain competitive in certain market segments.

Revenue Growth: 8.5% (2024) Profit Growth: 10.2% (2024) Market Share in the Orthopedic Industry: 5% (2024)

Medacta Group SA recorded solid revenue growth of 8.5% in 2024, driven by strong demand for its orthopedic products and innovative solutions. The profit growth of 10.2% during the same period indicates that the company is operating efficiently and was able to increase its profitability.

Through continuous investments in research and development, as well as the introduction of new products, the company has secured a strong position in the orthopedic industry. With a market share of 5%, Medacta has a significant presence and potential for further growth.

Analysts are optimistic that Medacta will continue to benefit from the aging population and the increasing demand for orthopedic solutions. The strategic focus on innovation and expansion into new markets could further support growth in the coming years.

Dividend yield: 2.5% (2024) Dividend growth: 5% (annually, average over the last 3 years)

Medacta Group SA paid out a dividend yield of 2.5% in 2024. The company has pursued a consistent dividend policy in recent years, with an average annual dividend growth of 5% over the last three years.

The reliability of Medacta's dividend payments is supported by its stable financial performance and strong market position. The company has a solid balance sheet and generates sufficient cash flow to sustain dividend payments. Analysts view the dividend as sustainable as long as the company maintains its current market position and no significant external economic challenges arise.